The Small Molecule VQ-101 Demonstrates Sustained Lysosomal Glucocerebrosidase (GCase) Activation in Idiopathic Parkinson’s Disease (S26.005)

Q: What does this research mean for the field?

The small molecule VQ-101 demonstrates sustained lysosomal glucocerebrosidase (GCase) activation when administered to patients with idiopathic Parkinson's disease. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Maurizio Facheris; Omer Siddiqui; Jurrian Van der Valk; Ingrid Koopmans; Kevin Hunt; Mackenzie Hagey; Beyer Jack; Harvey Wong; Philip Kremer; James Sullivan; Daniel Ysselstein

doi:10.1212/wnl.0000000000216945

June 9, 2026Neurology

The Small Molecule VQ-101 Demonstrates Sustained Lysosomal Glucocerebrosidase (GCase) Activation in Idiopathic Parkinson’s Disease (S26.005)

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the safety, tolerability, and pharmacological effects of VQ-101 in individuals with idiopathic Parkinson’s disease.
Oral administration of VQ-101 once daily for up to 12 weeks.
Assessment of pharmacokinetics and pharmacodynamics in participants with idiopathic Parkinson’s disease.
VQ-101 demonstrated sustained activation of glucocerebrosidase.
Participants tolerated VQ-101 well with no significant adverse effects reported.
Pharmacokinetic analysis indicated effective drug absorption over the study period.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Assesses VQ-101’s safety and glucocerebrosidase activation in idiopathic Parkinson’s disease, suggesting potential benefits.

Abstract

To assess the safety, tolerability, pharmacokinetic and pharmacodynamics of VQ-101 administered orally, once daily, for up to 12 weeks in people living with idiopathic Parkinson’s disease (iPD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Facheris et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf32afaef96ed7f055a7b https://doi.org/10.1212/wnl.0000000000216945

View at Publisher

Ask AI

Bookmark

Share

The Small Molecule VQ-101 Demonstrates Sustained Lysosomal Glucocerebrosidase (GCase) Activation in Idiopathic Parkinson’s Disease (S26.005)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

The Small Molecule VQ-101 Demonstrates Sustained Lysosomal Glucocerebrosidase (GCase) Activation in Idiopathic Parkinson’s Disease (S26.005)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading